Chapter 1

Platform and Price

Doximity runs the dominant professional network for U.S. physicians and rents access to that audience to drug makers and hospitals. The economics are unusual: 89% gross margins, roughly half of every revenue dollar converted to free cash flow, no debt, and $749 million of net cash [1]. Yet after management guided fiscal 2027 revenue growth to about 4%, down from north of 20%, the shares have fallen roughly 70% since September 2025. This chapter sets out what the company is, how it earns, and the question that fall poses.

Sources: FY2026 revenue and 85% physician reach, FY2026 Annual Report (Form 10-K) [2] [3]; free-cash-flow margin and net cash, Q4 FY2026 earnings call [4].

What Doximity is and how it earns

Doximity describes itself as the leading digital platform for U.S. medical professionals, with more than 3 million registered members as of March 31, 2026 — over 85% of U.S. physicians across all 50 states and every specialty, two-thirds of nurse practitioners and physician assistants, and roughly 90% of graduating medical students [5]. Membership is free. The network is the asset; the customers who pay are on the other side of it.

Those paying customers are chiefly pharmaceutical manufacturers and health systems, and they buy three families of product [6]:

• Marketing Solutions — the core of the business — let drug makers and health systems deliver branded clinical content and peer connections to specific physician audiences.
• Hiring Solutions provide digital recruiting into the network of active and passive medical candidates.
• Workflow Solutions are the free clinician tools — telehealth, on-call scheduling, digital fax, and a Clinical AI Suite — that keep physicians engaged and feed the data behind the marketing product.

The model is a two-sided network: physician engagement with the free tools widens the audience, which raises the value of the paid marketing product, which funds more tools [7]. Revenue is concentrated: the 125 customers that each spent more than $500,000 in fiscal 2026 accounted for about 83% of revenue [8]. Almost all of it — $608 million of $645 million — is subscription-based [9].

The financial record

Revenue rose from $116 million in fiscal 2020 to $645 million in fiscal 2026, and free cash flow expanded alongside it every year — an unbroken record that matters more here than any single year's figure [10].

Source: FY2026 Annual Report (Form 10-K), consolidated statements of operations and cash flows; free cash flow computed as operating cash flow less capital expenditure [11]. Doximity's own definition also nets capitalized software and reports $317M of free cash flow for FY2026, 49% of revenue [12].

The cash conversion is the standout feature. Capital spending is trivial — under $2 million in most years — so operating cash flow drops almost intact to free cash flow, which reached $317 million in fiscal 2026 on the company's own definition, or 49% of revenue [13]. For an investor who weighs the consistency of free cash flow, the seven-year line is the relevant fact: it has never gone backward.

The slowdown behind the metrics

Growth has been decelerating for two years, and the two subscription metrics management publishes tell the same story. The number of large customers keeps rising, but net revenue retention — the rate at which existing customers expand — has fallen from 157% in fiscal 2022 to 109% in fiscal 2026 [14]. Above 100% still means the installed base is growing, but the pace of that expansion has roughly halved.

Source: FY2026 Annual Report (Form 10-K), Key Business and Financial Metrics; revenue growth computed from reported revenue [15].

Management's guidance made the deceleration explicit. For fiscal 2027 it expects revenue of $664–676 million — about 4% growth at the midpoint — and an adjusted EBITDA margin of 49%, down from 55%, citing a step-up in AI compute costs it plans to carry through the year [16]. The stated cause is demand, not the platform: management describes the market for digital pharmaceutical advertising to healthcare professionals as soft, with policy uncertainty elevated and visibility limited, and expects that market to grow at or below 5% this year [17]. The 10-K carries the same caution: policy and macroeconomic uncertainty may slow decision-making and reduce discretionary marketing spend at pharmaceutical companies [18].

The re-rating

The market treated the slowdown as a change in kind, not degree. From a September 2025 quarter-end close of about $73, the shares fell to roughly $22 by mid-2026 — near a five-year low, and down close to 80% from the 2021 post-IPO peak above $100.

Source: daily closing prices, NYSE: DOCS (company price feed); calendar-quarter-end closes, with the final point at 10 July 2026.

At roughly $22, the equity is worth about $4.3 billion. Strip out the $749 million of net cash and the operating business is valued near $3.6 billion — around 11 times fiscal 2026 free cash flow, or about 22 times GAAP earnings before the cash offset [19]. That is a price a slow-growth business could carry; whether it is cheap depends entirely on whether 4% is a floor or a ceiling.

Balance sheet and control

Two facts frame the risk. First, there is effectively no solvency risk: Doximity carries no debt, held $749 million in cash and marketable securities at year-end, and generates cash every quarter [20]. It has been returning that cash aggressively — $432 million of stock repurchased in fiscal 2026, up from $116 million a year earlier, with $493 million of authorization remaining [21].

Second, the company is founder-controlled. Co-founder Jeffrey Tangney held about 29.9% of the company as of May 2026 [22] and serves as chief executive and board chair; the board has no independent chair and is classified into three staggered classes [23]. The insider alignment and the concentration of control are two sides of one fact, and the governance detail — including the dual-class voting structure — warrants its own examination later in this report.

The question this report answers

Doximity is a rare combination: a network that reaches most of its market, near-90% gross margins, half of revenue in free cash flow, net cash, a founder with a large personal stake, and a share price down some 70% in ten months. The central question is whether the collapse to roughly 4% guided growth marks the structural maturing of a near-saturated physician-marketing niche, or a cyclical trough in pharmaceutical marketing budgets that leaves the post-decline price offering a genuine margin of safety. Everything that follows is an attempt to distinguish the two.